for Journals by Title or ISSN
for Articles by Keywords
help

Publisher: Medknow Publishers   (Total: 426 journals)

 A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z  

        1 2 3 | Last   [Sort by number of followers]   [Restore default list]

Showing 1 - 200 of 426 Journals sorted alphabetically
Acta Medica Intl.     Open Access   (SJR: 0.101, CiteScore: 0)
Advanced Arab Academy of Audio-Vestibulogy J.     Open Access  
Advanced Biomedical Research     Open Access  
Advances in Human Biology     Open Access   (Followers: 4)
Advances in Skeletal Muscle Function Assessment     Open Access  
African J. for Infertility and Assisted Conception     Open Access  
African J. of Medical and Health Sciences     Open Access   (Followers: 2)
African J. of Paediatric Surgery     Open Access   (Followers: 7, SJR: 0.25, CiteScore: 1)
African J. of Trauma     Open Access   (Followers: 1)
Ain-Shams J. of Anaesthesiology     Open Access   (Followers: 3)
Al-Azhar Assiut Medical J.     Open Access  
Al-Basar Intl. J. of Ophthalmology     Open Access   (Followers: 1)
Alexandria J. of Pediatrics     Open Access  
Ancient Science of Life     Open Access   (Followers: 5)
Anesthesia : Essays and Researches     Open Access   (Followers: 10)
Annals of African Medicine     Open Access   (Followers: 2, SJR: 0.258, CiteScore: 1)
Annals of Bioanthropology     Open Access   (Followers: 4)
Annals of Cardiac Anaesthesia     Open Access   (Followers: 14, SJR: 0.308, CiteScore: 1)
Annals of Indian Academy of Neurology     Open Access   (Followers: 3, SJR: 0.434, CiteScore: 1)
Annals of Indian Academy of Otorhinolaryngology Head and Neck Surgery     Open Access  
Annals of Indian Psychiatry     Open Access  
Annals of Maxillofacial Surgery     Open Access   (Followers: 6)
Annals of Medical and Health Sciences Research     Open Access   (Followers: 7)
Annals of Nigerian Medicine     Open Access   (Followers: 1)
Annals of Pediatric Cardiology     Open Access   (Followers: 12, SJR: 0.352, CiteScore: 1)
Annals of Saudi Medicine     Open Access   (SJR: 0.238, CiteScore: 1)
Annals of Thoracic Medicine     Open Access   (Followers: 6, SJR: 0.524, CiteScore: 1)
Annals of Tropical Medicine and Public Health     Open Access   (Followers: 13, SJR: 0.152, CiteScore: 0)
Annals of Tropical Pathology     Open Access  
Apollo Medicine     Open Access  
APOS Trends in Orthodontics     Open Access   (Followers: 1)
Arab J. of Interventional Radiology     Open Access  
Archives of Cardiovascular Imaging     Open Access   (Followers: 2, SJR: 0.187, CiteScore: 0)
Archives of Intl. Surgery     Open Access   (Followers: 10, SJR: 0.302, CiteScore: 1)
Archives of Medicine and Health Sciences     Open Access   (Followers: 3)
Archives of Medicine and Surgery     Open Access  
Archives of Pharmacy Practice     Open Access   (Followers: 10, SJR: 0.102, CiteScore: 0)
Archives of Trauma Research     Open Access   (Followers: 3, SJR: 0.37, CiteScore: 2)
Asia Pacific J. of Clinical Trials : Nervous System Diseases     Open Access  
Asia-Pacific J. of Oncology Nursing     Open Access   (Followers: 5)
Asian J. of Andrology     Open Access   (Followers: 1, SJR: 0.856, CiteScore: 2)
Asian J. of Neurosurgery     Open Access   (Followers: 2)
Asian J. of Oncology     Open Access   (Followers: 2)
Asian J. of Transfusion Science     Open Access   (Followers: 1, SJR: 0.35, CiteScore: 1)
Asian Pacific J. of Reproduction     Open Access   (SJR: 0.227, CiteScore: 1)
Asian Pacific J. of Tropical Biomedicine     Open Access   (Followers: 2, SJR: 0.491, CiteScore: 2)
Asian Pacific J. of Tropical Medicine     Open Access   (Followers: 1, SJR: 0.561, CiteScore: 2)
Astrocyte     Open Access  
Avicenna J. of Medicine     Open Access   (Followers: 1)
AYU : An international quarterly journal of research in Ayurveda     Open Access   (Followers: 6)
Benha Medical J.     Open Access  
Biomedical and Biotechnology Research J.     Open Access  
BLDE University J. of Health Sciences     Open Access  
Brain Circulation     Open Access   (Followers: 1)
Bulletin of Faculty of Physical Therapy     Open Access   (Followers: 1)
Canadian J. of Rural Medicine     Full-text available via subscription   (SJR: 0.202, CiteScore: 0)
Cancer Translational Medicine     Open Access   (Followers: 2)
Cardiology Plus     Open Access   (Followers: 1)
Chinese Medical J.     Open Access   (Followers: 10, SJR: 0.52, CiteScore: 1)
CHRISMED J. of Health and Research     Open Access   (Followers: 2)
Clinical Cancer Investigation J.     Open Access  
Clinical Dermatology Review     Open Access   (Followers: 4)
Clinical Trials in Degenerative Diseases     Open Access  
Clinical Trials in Orthopedic Disorders     Open Access  
Community Acquired Infection     Open Access  
Conservation and Society     Open Access   (Followers: 10, SJR: 0.811, CiteScore: 2)
Contemporary Clinical Dentistry     Open Access   (Followers: 4, SJR: 0.353, CiteScore: 1)
Current Medical Issues     Open Access   (Followers: 1)
CytoJ.     Open Access   (Followers: 2, SJR: 0.543, CiteScore: 1)
Delta J. of Ophthalmology     Open Access  
Dental Hypotheses     Open Access   (Followers: 4, SJR: 0.152, CiteScore: 0)
Dental Research J.     Open Access   (Followers: 12, SJR: 0.416, CiteScore: 1)
Dentistry and Medical Research     Open Access  
Digital Medicine     Open Access  
Drug Development and Therapeutics     Open Access  
Education for Health     Open Access   (Followers: 6, SJR: 0.242, CiteScore: 0)
Egyptian J. of Bronchology     Open Access  
Egyptian J. of Cardiothoracic Anesthesia     Open Access  
Egyptian J. of Cataract and Refractive Surgery     Open Access   (Followers: 1, SJR: 1.799, CiteScore: 2)
Egyptian J. of Chest Diseases and Tuberculosis     Open Access   (Followers: 3, SJR: 0.155, CiteScore: 0)
Egyptian J. of Dermatology and Venerology     Open Access   (Followers: 1)
Egyptian J. of Haematology     Open Access   (Followers: 1)
Egyptian J. of Internal Medicine     Open Access   (Followers: 1)
Egyptian J. of Obesity, Diabetes and Endocrinology     Open Access   (Followers: 1)
Egyptian J. of Otolaryngology     Open Access   (Followers: 2)
Egyptian J. of Psychiatry     Open Access   (Followers: 2)
Egyptian J. of Surgery     Open Access   (Followers: 1)
Egyptian Nursing J.     Open Access  
Egyptian Orthopaedic J.     Open Access   (Followers: 2)
Egyptian Pharmaceutical J.     Open Access   (Followers: 1)
Egyptian Retina J.     Open Access  
Egyptian Rheumatology and Rehabilitation     Open Access   (Followers: 2)
Endodontology     Open Access  
Endoscopic Ultrasound     Open Access   (SJR: 0.822, CiteScore: 2)
Environmental Disease     Open Access   (Followers: 3)
Eurasian J. of Pulmonology     Open Access  
European J. of Dentistry     Open Access   (Followers: 2, SJR: 0.749, CiteScore: 2)
European J. of General Dentistry     Open Access   (Followers: 1, SJR: 0.12, CiteScore: 0)
European J. of Prosthodontics     Open Access   (Followers: 3)
European J. of Psychology and Educational Studies     Open Access   (Followers: 11, SJR: 0.113, CiteScore: 0)
Fertility Science and Research     Open Access  
Formosan J. of Surgery     Open Access   (SJR: 0.112, CiteScore: 0)
Genome Integrity     Open Access   (Followers: 2, SJR: 0.153, CiteScore: 0)
Glioma     Open Access  
Global J. of Transfusion Medicine     Open Access   (Followers: 1)
Gynecology and Minimally Invasive Therapy     Open Access   (SJR: 0.311, CiteScore: 1)
Hamdan Medical J.     Open Access  
Heart and Mind     Open Access  
Heart India     Open Access   (Followers: 1)
Heart Views     Open Access   (Followers: 2)
Hepatitis B Annual     Open Access   (Followers: 3)
Ibnosina J. of Medicine and Biomedical Sciences     Open Access  
IJS Short Reports     Open Access  
Imam J. of Applied Sciences     Open Access  
Indian Dermatology Online J.     Open Access   (Followers: 3)
Indian J. of Allergy, Asthma and Immunology     Open Access   (Followers: 1)
Indian J. of Anaesthesia     Open Access   (Followers: 7, SJR: 0.478, CiteScore: 1)
Indian J. of Burns     Open Access   (Followers: 1)
Indian J. of Cancer     Open Access   (Followers: 1, SJR: 0.361, CiteScore: 1)
Indian J. of Cerebral Palsy     Open Access   (Followers: 1)
Indian J. of Community Medicine     Open Access   (Followers: 2, SJR: 0.37, CiteScore: 1)
Indian J. of Dental Research     Open Access   (Followers: 5, SJR: 0.266, CiteScore: 1)
Indian J. of Dental Sciences     Open Access  
Indian J. of Dentistry     Open Access   (Followers: 1)
Indian J. of Dermatology     Open Access   (Followers: 2, SJR: 0.468, CiteScore: 1)
Indian J. of Dermatology, Venereology and Leprology     Open Access   (Followers: 4, SJR: 0.445, CiteScore: 1)
Indian J. of Dermatopathology and Diagnostic Dermatology     Open Access  
Indian J. of Drugs in Dermatology     Open Access   (Followers: 1, SJR: 0.791, CiteScore: 1)
Indian J. of Endocrinology and Metabolism     Open Access   (Followers: 4, SJR: 0.568, CiteScore: 1)
Indian J. of Health Sciences and Biomedical Research KLEU     Open Access   (Followers: 2)
Indian J. of Medical and Paediatric Oncology     Open Access   (SJR: 0.425, CiteScore: 1)
Indian J. of Medical Microbiology     Open Access   (Followers: 2, SJR: 0.503, CiteScore: 1)
Indian J. of Medical Research     Open Access   (Followers: 4, SJR: 0.656, CiteScore: 1)
Indian J. of Medical Sciences     Open Access   (Followers: 2, SJR: 0.102, CiteScore: 0)
Indian J. of Multidisciplinary Dentistry     Open Access   (Followers: 1)
Indian J. of Nephrology     Open Access   (Followers: 2, SJR: 0.347, CiteScore: 1)
Indian J. of Nuclear Medicine     Open Access   (Followers: 2, SJR: 0.23, CiteScore: 0)
Indian J. of Occupational and Environmental Medicine     Open Access   (Followers: 3, SJR: 0.225, CiteScore: 1)
Indian J. of Ophthalmology     Open Access   (Followers: 4, SJR: 0.498, CiteScore: 1)
Indian J. of Oral Health and Research     Open Access  
Indian J. of Oral Sciences     Open Access   (Followers: 1)
Indian J. of Orthopaedics     Open Access   (Followers: 8, SJR: 0.392, CiteScore: 1)
Indian J. of Otology     Open Access   (Followers: 1, SJR: 0.199, CiteScore: 0)
Indian J. of Paediatric Dermatology     Open Access   (Followers: 2)
Indian J. of Pain     Open Access   (Followers: 2)
Indian J. of Palliative Care     Open Access   (Followers: 6, SJR: 0.454, CiteScore: 1)
Indian J. of Pathology and Microbiology     Open Access   (Followers: 2, SJR: 0.276, CiteScore: 1)
Indian J. of Pharmacology     Open Access   (SJR: 0.412, CiteScore: 1)
Indian J. of Plastic Surgery     Open Access   (Followers: 12, SJR: 0.311, CiteScore: 0)
Indian J. of Psychiatry     Open Access   (Followers: 3, SJR: 0.408, CiteScore: 1)
Indian J. of Psychological Medicine     Open Access   (SJR: 0.368, CiteScore: 1)
Indian J. of Public Health     Open Access   (Followers: 1)
Indian J. of Radiology and Imaging     Open Access   (Followers: 4)
Indian J. of Research in Homoeopathy     Open Access  
Indian J. of Respiratory Care     Open Access  
Indian J. of Rheumatology     Open Access   (Followers: 1, SJR: 0.119, CiteScore: 0)
Indian J. of Sexually Transmitted Diseases and AIDS     Open Access   (Followers: 2, SJR: 0.34, CiteScore: 0)
Indian J. of Social Psychiatry     Open Access   (Followers: 2)
Indian J. of Transplantation     Open Access  
Indian J. of Urology     Open Access   (Followers: 3, SJR: 0.434, CiteScore: 1)
Indian J. of Vascular and Endovascular Surgery     Open Access   (Followers: 2)
Indian Spine J.     Open Access  
Industrial Psychiatry J.     Open Access   (Followers: 2)
Intervention     Open Access   (Followers: 1)
Intl. Archives of Health Sciences     Open Access  
Intl. J. of Abdominal Wall and Hernia Surgery     Open Access   (Followers: 1)
Intl. J. of Academic Medicine     Open Access  
Intl. J. of Advanced Medical and Health Research     Open Access  
Intl. J. of Applied and Basic Medical Research     Open Access  
Intl. J. of Clinical and Experimental Physiology     Open Access   (Followers: 1)
Intl. J. of Clinicopathological Correlation     Open Access   (Followers: 1)
Intl. J. of Community Dentistry     Open Access  
Intl. J. of Critical Illness and Injury Science     Open Access   (Followers: 1, SJR: 0.192, CiteScore: 0)
Intl. J. of Educational and Psychological Researches     Open Access   (Followers: 4)
Intl. J. of Environmental Health Engineering     Open Access   (Followers: 1)
Intl. J. of Forensic Odontology     Open Access   (Followers: 1)
Intl. J. of Green Pharmacy     Open Access   (Followers: 5, SJR: 0.142, CiteScore: 0)
Intl. J. of Growth Factors and Stem Cells in Dentistry     Open Access  
Intl. J. of Health & Allied Sciences     Open Access   (Followers: 3)
Intl. J. of Health System and Disaster Management     Open Access   (Followers: 3)
Intl. J. of Heart Rhythm     Open Access  
Intl. J. of Medicine and Public Health     Open Access   (Followers: 6)
Intl. J. of Mycobacteriology     Open Access   (SJR: 0.535, CiteScore: 1)
Intl. J. of Noncommunicable Diseases     Open Access  
Intl. J. of Nutrition, Pharmacology, Neurological Diseases     Open Access   (Followers: 4, SJR: 0.17, CiteScore: 0)
Intl. J. of Oral Health Sciences     Open Access   (Followers: 3)
Intl. J. of Orofacial Biology     Open Access   (Followers: 1)
Intl. J. of Orofacial Research     Open Access   (Followers: 1)
Intl. J. of Orthodontic Rehabilitation     Open Access   (Followers: 1)
Intl. J. of Pedodontic Rehabilitation     Open Access  
Intl. J. of Pharmaceutical Investigation     Open Access   (Followers: 1)
Intl. J. of Preventive Medicine     Open Access   (Followers: 1, SJR: 0.623, CiteScore: 1)
Intl. J. of Shoulder Surgery     Open Access   (Followers: 5, SJR: 0.653, CiteScore: 1)
Intl. J. of the Cardiovascular Academy     Open Access   (SJR: 0.105, CiteScore: 0)
Intl. J. of Trichology     Open Access   (SJR: 0.4, CiteScore: 1)
Intl. J. of Yoga     Open Access   (Followers: 15)
Intl. J. of Yoga : Philosophy, Psychology and Parapsychology     Open Access   (Followers: 6)
Iranian J. of Nursing and Midwifery Research     Open Access   (Followers: 3)
Iraqi J. of Hematology     Open Access  
J. of Academy of Medical Sciences     Open Access  

        1 2 3 | Last   [Sort by number of followers]   [Restore default list]

Similar Journals
Journal Cover
Indian Journal of Rheumatology
Journal Prestige (SJR): 0.119
Number of Followers: 1  

  This is an Open Access Journal Open Access journal
ISSN (Print) 0973-3698 - ISSN (Online) 0973-3701
Published by Medknow Publishers Homepage  [426 journals]
  • But I Have Promises to Keep……

    • Authors: Vikas Agarwal
      Pages: 1 - 1
      Abstract: Vikas Agarwal
      Indian Journal of Rheumatology 2019 14(1):1-1

      Citation: Indian Journal of Rheumatology 2019 14(1):1-1
      PubDate: Thu,14 Mar 2019
      DOI: 10.4103/0973-3698.254212
      Issue No: Vol. 14, No. 1 (2019)
       
  • Challenges in assessing the disease activity of takayasu arteritis

    • Authors: Durga Prasanna Misra, Anupam Wakhlu
      Pages: 2 - 3
      Abstract: Durga Prasanna Misra, Anupam Wakhlu
      Indian Journal of Rheumatology 2019 14(1):2-3

      Citation: Indian Journal of Rheumatology 2019 14(1):2-3
      PubDate: Thu,14 Mar 2019
      DOI: 10.4103/injr.injr_19_19
      Issue No: Vol. 14, No. 1 (2019)
       
  • Is rituximab “The Wonder Drug” for antineutrophil cytoplasmic
           antibodies-associated vasculitis?

    • Authors: Saket Jha, GSRSNK Naidu, Aman Sharma
      Pages: 4 - 6
      Abstract: Saket Jha, GSRSNK Naidu, Aman Sharma
      Indian Journal of Rheumatology 2019 14(1):4-6

      Citation: Indian Journal of Rheumatology 2019 14(1):4-6
      PubDate: Thu,14 Mar 2019
      DOI: 10.4103/0973-3698.254190
      Issue No: Vol. 14, No. 1 (2019)
       
  • Advanced therapies for inflammatory rheumatic diseases in resource-poor
           settings

    • Authors: Vinod Chandran
      Pages: 7 - 8
      Abstract: Vinod Chandran
      Indian Journal of Rheumatology 2019 14(1):7-8

      Citation: Indian Journal of Rheumatology 2019 14(1):7-8
      PubDate: Thu,14 Mar 2019
      DOI: 10.4103/0973-3698.254191
      Issue No: Vol. 14, No. 1 (2019)
       
  • Utility of CD64 expression on neutrophils as a marker to differentiate
           infectious versus noninfectious disease flares in autoimmune disorders

    • Authors: Ashutosh K Mangalam, Rajwardhan Yadav
      Pages: 9 - 11
      Abstract: Ashutosh K Mangalam, Rajwardhan Yadav
      Indian Journal of Rheumatology 2019 14(1):9-11

      Citation: Indian Journal of Rheumatology 2019 14(1):9-11
      PubDate: Thu,14 Mar 2019
      DOI: 10.4103/0973-3698.254192
      Issue No: Vol. 14, No. 1 (2019)
       
  • Rituximab in relapsed/refractory antineutrophil cytoplasmic antibody
           associated vasculitis: A single-center prospective observational study

    • Authors: Ekbote Gayatri, Tanna Dhaval, Negalur Natasha, Bindroo Muzaffar, Raval Dhiren, Sharma Lucky, Rajiva Gupta
      Pages: 12 - 16
      Abstract: Ekbote Gayatri, Tanna Dhaval, Negalur Natasha, Bindroo Muzaffar, Raval Dhiren, Sharma Lucky, Rajiva Gupta
      Indian Journal of Rheumatology 2019 14(1):12-16
      Background: Induction with cyclophosphamide (CYC) and glucocorticoids in antineutrophil cytoplasmic antibody-associated vasculitis (AAV) has a relapse of 30%–50%. Studies show that rituximab (RTX) is superior to CYC in refractory/relapsed AAV. We prospectively analyzed efficacy and safety of RTX in CYC-failed cases of AAV.Methods: Patients with AAV who relapsed or were refractory to CYC therapy were given RTX 1 gm at 0 and 15 days, followed by maintenance with 500 mg every 4–6 months. All patients received oral prednisolone. Disease activity was defined by Birmingham Vasculitis Activity Score/Wegener's granulomatosis (BVAS/WG). Remission was defined by the European League Against Rheumatism criteria.Results: From August 2012 to July 2018, 67 patients with AAV were seen at our center; 21 patients who relapsed after inductions with CYC or were refractory to CYC received RTX; 8 (38%) were refractory and 13 (62%) were relapsed AAV; 20 were anti-proteinase 3 positive and 1 was anti-myeloperoxidase positive. All were granulomatosis with polyangiitis (GPA). Mean time to relapse was 12.04 ± 7.8 months. Most common indication for RTX was lung followed by ophthalmic, renal, ear nose throat, and nervous system involvement. Median follow-up after induction with RTX was 24 months.Mean BVAS/WG was 11.2 at baseline, 0.66 at the end of 3 months, 0.16 at the end of 6 months, and remained stable at that value at 18 months. At 24 months, 16 patients (76.19%) remained in remission. One was refractory to RTX treatment even after 2 years. Two patients died and two were still under follow-up.Conclusion: In our experience, RTX is a good induction and maintenance strategy for relapsed/refractory AAV.
      Citation: Indian Journal of Rheumatology 2019 14(1):12-16
      PubDate: Thu,14 Mar 2019
      DOI: 10.4103/injr.injr_138_18
      Issue No: Vol. 14, No. 1 (2019)
       
  • Prescribing patterns and safety of biologics in immune-mediated rheumatic
           diseases: Karnataka biologics cohort study group experience

    • Authors: Vineeta Shobha, Vijay Rao, Anu Mohan Desai, Ramesh Jois, Chandrashekara Srikantiah, BG Dharmanand, Sharath Kumar, Pradeep Kumar, Chethana Dharmapalaiah, KM Mahendranath, Shiva Prasad, Manisha Daware, Yogesh Singh, Uma Karjigi
      Pages: 17 - 20
      Abstract: Vineeta Shobha, Vijay Rao, Anu Mohan Desai, Ramesh Jois, Chandrashekara Srikantiah, BG Dharmanand, Sharath Kumar, Pradeep Kumar, Chethana Dharmapalaiah, KM Mahendranath, Shiva Prasad, Manisha Daware, Yogesh Singh, Uma Karjigi
      Indian Journal of Rheumatology 2019 14(1):17-20
      Introduction: Biologics are widely used in Autoimmune rheumatologic diseases (AIRDs), however the need to capture real life data which monitors indications, adverse reactions cannot be over emphasized. Methods: This is a cross-sectional ambidirectional multi-center study conducted over 8 months from January 2016 to August 2016, across 12 tertiary care rheumatology centers in Karnataka, India conducted by members of the Karnataka Rheumatology Association. Results: The most common biologic prescribed is tumour necrosis factor antagonist etanercept. Commonest indication for biologics being Spondyloarthropathy group of disorders. The most common cause for stopping biologics is clinical improvement. Only 4.8% of patents discontinued biologics due to ADRs. Conclusion: The prescribing patterns, mode of use, prebiologics screening methods, and adverse event profile are similar across centres. Pre-screening for latent tuberculosis (TB) is consistent across centres, and TB prophylaxis appears to be effective in preventing its reactivation.
      Citation: Indian Journal of Rheumatology 2019 14(1):17-20
      PubDate: Thu,14 Mar 2019
      DOI: 10.4103/injr.injr_79_18
      Issue No: Vol. 14, No. 1 (2019)
       
  • Pentraxin 3 is better than conventional inflammatory markers for disease
           activity assessment in takayasu arteritis

    • Authors: Phani Kumar Devarasetti, Rajendra Varaprasad Irlapati, Liza Rajasekhar
      Pages: 21 - 27
      Abstract: Phani Kumar Devarasetti, Rajendra Varaprasad Irlapati, Liza Rajasekhar
      Indian Journal of Rheumatology 2019 14(1):21-27
      Objective: The objective of this study is to measure plasma pentraxin 3 (PTX3) levels in Takayasu arteritis (TA) patients and to compare the accuracy of PTX3, high-sensitive C-reactive protein (hsCRP), and erythrocyte sedimentation rate (ESR) in distinguishing active disease from the inactive disease.Methods: In a prospective, cross-sectional study, TA patients fulfilling 1990 American College of Rheumatology criteria and healthy controls were enrolled in this study. The Indian Takayasu Clinical Activity Score (ITAS 2010) and ITAS ESR were recorded. Patients were divided into active, grumbling and inactive disease using physician global assessment. Plasma PTX3, hsCRP, and ESR were measured. Receiver operating curves for PTX3 (pg/ml), hsCRP (mg/L), and ESR (mm at 1 h) were constructed to differentiate active from the inactive disease. Inter-group comparisons were made using Mann–Whitney test.Results: Forty patients and 20 controls with median age of 26 and 24 years, respectively, were enrolled in this study. Median disease duration was 2 years. Fourteen patients had active, 8 grumbling, and 18 inactive disease. ITAS 2010 and ITAS ESR in active disease (5 [3–8.5], 7.5 [5–11.5]) were significantly higher than grumbling (0.6 (0–1.5], 2.5 [1–4.5]) or inactive disease (0.5 [0–1.3], 2 [1.7–3]) (P = 0.001). PTX3 (pg/mL) was higher in cases (505 [261–1358]) as compared to that of controls (317 [135–450]) (P < 0.026), in active disease (1335 [464–2128]) was higher than grumbling (689 [246–2114]), but significantly higher than inactive TA (369 [145–512]) (P < 0.001). ESR (mm/h) and hsCRP (mg/L) of 49 (33–61.2), 12.9 (4–21), respectively, in active disease was similar to grumbling (44 [31–63], 10.7 [3–14.7]), but significantly higher than inactive disease (38 [24–45], 1.8 [1.4–2.2]) (P = 0.03). Sensitivity, specificity, and area under the curve for ESR (>46 mm), hsCRP (17.1 mg/L), PTX3 (>745 pg/ml) was (55, 89, and 0.72), (46, 89, and 0.75), and (64, 95, and 0.82), respectively.Conclusion: Elevated PTX3 in TA demonstrates more accuracy than hsCRP and ESR in differentiating active from the inactive disease. These biomarkers may differentiate grumbling from inactive disease better than ITAS2010 or ITAS-ESR.
      Citation: Indian Journal of Rheumatology 2019 14(1):21-27
      PubDate: Thu,14 Mar 2019
      DOI: 10.4103/injr.injr_95_18
      Issue No: Vol. 14, No. 1 (2019)
       
  • Serum sclerostin levels in rheumatoid arthritis and correlation with
           disease activity and bone mineral density

    • Authors: Urmila Dhakad, Rasmi Ranjan Sahoo, Akhil Pawan Goel, Sourav Pradhan, Ragini Srivastava, Siddharth Kumar Das
      Pages: 28 - 31
      Abstract: Urmila Dhakad, Rasmi Ranjan Sahoo, Akhil Pawan Goel, Sourav Pradhan, Ragini Srivastava, Siddharth Kumar Das
      Indian Journal of Rheumatology 2019 14(1):28-31
      Background: This study aims to assess serum sclerostin, an inhibitor of the Wnt/β-catenin signaling pathway, in rheumatoid arthritis (RA) and its correlation with disease activity and bone mineral density (BMD).Methods: RA patients (>18 years) fulfilling the ACR/EULAR (2010) criteria for RA were included. Postmenopausal women, those with other autoimmune diseases, secondary causes of osteoporosis, severe vitamin D deficiency, chronic liver disease, chronic kidney disease stage 3 and above, and those patients on anticonvulsants were excluded. Rheumatoid factor, anticitrullinated protein antibody, 25-OH Vitamin D estimation, plain radiographs of hands, and BMD measurement by dual-energy X-ray absorpiometry were done in patients. Disease activity was assessed by clinical disease activity index (CDAI). Serum sclerostin levels in RA patients and controls (age and sex matched) were measured by commercial enzyme-linked immunosorbent assay (ELISA) and the relationship of sclerostin with low BMD, ESR, CDAI, and erosion were explored.Results: The mean age of patients (n = 47) was 32.7 ± 6.8 years and mean disease duration was 4.2 ± 2 years. All patients were women, mean body mass index was 22.38±4.4 and mean vitamin D level was 27.9±16.4 ng/ml. 25.5% of RA patients had low BMD at least one site (Z-score: −2 or less). Serum sclerostin was significantly higher in patients compared to controls (8422 ± 3655 pg/ml vs. 6479 ± 1510 pg/ml, P = 0.002). Serum sclerostin levels did not correlate significantly with ESR (r = −0.31 and P = 0.048), CDAI (r = −0.11 and P = 0.45), BMD at lumbar spine (L1–L4, r = 0.14, and P = 0.35), femur neck (r = 0.06 and P = 0.67), and wrist (r = 0.12 and P = 0.41).Conclusion: Serum sclerostin levels were elevated in RA patients but did not correlate with disease activity and BMD.
      Citation: Indian Journal of Rheumatology 2019 14(1):28-31
      PubDate: Thu,14 Mar 2019
      DOI: 10.4103/injr.injr_113_18
      Issue No: Vol. 14, No. 1 (2019)
       
  • Dual antibody status predicts sustained remission in patients with
           rheumatoid arthritis

    • Authors: Praveen Pratap Jadhav, Jaya Dilip Avhad, Mahendra Mahajan, Asmanaz Mehemud Patel, Hemant Ramchandra Gavli, Janhavee Praveen Jadhav, Vaibhav Khandelwal
      Pages: 32 - 36
      Abstract: Praveen Pratap Jadhav, Jaya Dilip Avhad, Mahendra Mahajan, Asmanaz Mehemud Patel, Hemant Ramchandra Gavli, Janhavee Praveen Jadhav, Vaibhav Khandelwal
      Indian Journal of Rheumatology 2019 14(1):32-36
      Background: Rheumatoid factor (RF) and anti-cyclic citrullinated protein (ACCP) estimation have been used to improve the diagnosis of rheumatoid arthritis (RA). However, their role in prognostication of RA, individually and in combination, is not well studied. This is, especially, true for Indian patients.Methods: Consecutive 945 patients who had their RF and ACCP determined were included in the study. They were followed up for 3 months to 24 months. Swollen joint count, erythrocyte sedimentation rate, disease activity score 28 (DAS 28), and Indian version of Health Assessment Questionnaire (HAQ) were checked during each visit. They were treated with conventional disease-modifying agents (DMARDS).Results: At presentation, patients with both antibodies positive had the most severe disease, while those with both antibodies negative had the least severe disease. Among discordant antibody status (one antibody positive and the other negative), patients with ACCP positivity presented with higher disease activity than with RF positivity. Patients with dual antibody positivity were much less likely to be in remission than with both negative antibodies. The percentage of patients in remission were 34.2, 29.5, 32.4, and 24.7, respectively, for RF−/ACCP−, ACCP+/RF−, ACCP−/RF+, and ACCP+/RF+. Both, ACCP (odds ratio [OR]: 0.76; 95% confidence interval [CI]: 0.74–0.78) and RF (OR: 0.68; 95% CI: 0.66–0.70) positivity were associated with lower odds of sustained remission (P < 0.05).Conclusion: Dual antibody-positive status at presentation carries poor prognosis, higher disease activity, higher HAQ score, and lesser chance of remission in RA patients with conventional treatment. Patients with both antibodies negative status had the best prognosis. Although patients with discordant antibody status had an intermediate prognosis, the ones with ACCP had higher disease activity at follow-up.
      Citation: Indian Journal of Rheumatology 2019 14(1):32-36
      PubDate: Thu,14 Mar 2019
      DOI: 10.4103/injr.injr_107_18
      Issue No: Vol. 14, No. 1 (2019)
       
  • Utility of anti-carbamylated protein antibodies in the diagnosis of early
           rheumatoid arthritis

    • Authors: Ashraf H Mohamed, Asmaa Enein, Noha Abdelsalam, Mona Balata, Sameh Abdellatif, Ehsan Rizk, Ahmed Fathy
      Pages: 37 - 41
      Abstract: Ashraf H Mohamed, Asmaa Enein, Noha Abdelsalam, Mona Balata, Sameh Abdellatif, Ehsan Rizk, Ahmed Fathy
      Indian Journal of Rheumatology 2019 14(1):37-41
      Background: Anti-carbamylated protein (anti-CarP) antibodies are present in patients with Rheumatoid arthritis (RA) and may present before disease onset. Our aim is to investigate the diagnostic value of anti-CarP antibody in Egyptian RA patients.Methods: This cross-sectional study included 96 RA patients (56 patients with early disease and 40 patients with established disease) and 60 healthy controls. Demographic and clinical data, smoking status, and disease activity score were recorded. Laboratory tests included erythrocyte sedimentation rate, C-reactive protein, rheumatoid factor, anti-citrullinated protein antibodies, and anti-CarP antibody.Results: Anti-CarP antibody levels in RA patients were significantly higher than in controls (8.80 ± 5.95 vs. 2.19 ± 1.01, P < 0.0001). Out of 96 RA patients; 74 (77.1%) were positive for anti -CarP anti body including 47patients with early RA while only 5 subjects (8.3%) in control group were positive. Receiver-operating characteristic curve study for diagnostic efficacy of anti-CarP antibody in early RA diagnosis demonstrated a significant area under the curve, 0.950 (95% confidence interval, 0.912–0.987, P < 0.0001) and yielded a sensitivity of 85.4%, a specificity of 93.3%, a positive predictive value of 0.90, and a negative predictive value of 0.86.Conclusion: Anti-CarP antibody is a useful biomarker for early RA diagnosis.
      Citation: Indian Journal of Rheumatology 2019 14(1):37-41
      PubDate: Thu,14 Mar 2019
      DOI: 10.4103/injr.injr_110_18
      Issue No: Vol. 14, No. 1 (2019)
       
  • A cross-sectional study of different rheumatic diseases and their
           respective comorbidities at a tertiary care hospital in India

    • Authors: Baikan Saiteja Yadav, Arindam Nandy Roy, Syeda Sana Fatima
      Pages: 42 - 48
      Abstract: Baikan Saiteja Yadav, Arindam Nandy Roy, Syeda Sana Fatima
      Indian Journal of Rheumatology 2019 14(1):42-48
      Background: Rheumatic diseases have many outcomes, but less understood are many manifestations of additional health conditions that are associated with these diseases called co-morbidities. The more co-morbid illnesses one has, the greater the interference with medical management of rheumatic diseases. It is important to recognize such illnesses and to account for them in the care of the individual patient. There are few studies pertaining to different co-morbidities associated with rheumatic conditions. Therefore, this study was carried out to evaluate different rheumatic diseases and their frequency, associated co-morbid conditions and their variation based on age and body mass index (BMI). Methods: This cross sectional study was designed to survey 1000 consecutive patients who were diagnosed to have rheumatic diseases for co-morbidities at our institution. Patients of either gender with age ≥18 years were included. Data was collected regarding demographics detail, diagnosed disease and co-morbid condition. Analysis was done by IBM SPSS version 17.0 and R version 3.4, the association of rheumatic disease and co-morbidity with age and BMI was analyzed using Chi-square test. Results: We found that that rheumatic disease and co-morbidity increased significantly with age and body mass index (BMI) (P < 0.005). A substantial proportion of patients with rheumatic diseases (45%) were foud to have co-morbidities. The most common amongst them are hypertension, hypothyroidism and diabetes mellitus in descending order of frequency.Conclusion: C-morbidities which are amenable to therapeutic measures are common in individuals with rheumatic diseases. Early detection of such co-morbid condition is helpful should be an integral part of rheumatology patient care.
      Citation: Indian Journal of Rheumatology 2019 14(1):42-48
      PubDate: Thu,14 Mar 2019
      DOI: 10.4103/injr.injr_112_18
      Issue No: Vol. 14, No. 1 (2019)
       
  • Management of pain in rheumatic diseases

    • Authors: Neha Goyal, Mohit Goyal, Vinod Ravindran
      Pages: 49 - 56
      Abstract: Neha Goyal, Mohit Goyal, Vinod Ravindran
      Indian Journal of Rheumatology 2019 14(1):49-56
      Pain is often the presenting symptom of many rheumatic diseases, the predominant disabling symptom, the reason for frequent visits to the physician and a major cause of medical absenteeism, loss of work hours, and financial burden on the society. Pain in rheumatic diseases is now understood to be a result of interplay of inflammation, tissue damage, and neurogenic responses. Besides control of inflammation, the structural changes, central sensitization, and the associated issues of disturbances of sleep, mood, and cognition also need to be addressed. Apart from the useful addition of neuromodulators to our traditional repertoire of pain medications consisting of analgesics, nonsteroidal anti-inflammatory drugs, steroids, and opioids, there is a place for interventions in situations where pain persists even after reasonable control of widespread inflammation. These interventions are mostly percutaneous and have found applications in inflammatory, structural, as well as neurogenic pain. Interventional spine procedures, platelet-rich plasma therapy, ozone therapy, and radiofrequency ablation of neural structures have added new dimensions to the management of pain.
      Citation: Indian Journal of Rheumatology 2019 14(1):49-56
      PubDate: Thu,14 Mar 2019
      DOI: 10.4103/injr.injr_88_18
      Issue No: Vol. 14, No. 1 (2019)
       
  • Current treatment of osteoporosis

    • Authors: Subramanian Nallasivan
      Pages: 57 - 60
      Abstract: Subramanian Nallasivan
      Indian Journal of Rheumatology 2019 14(1):57-60
      Osteoporosis is ever increasing as life expectancy continues to increase across the world. Hypovitaminosis D has been found to be prevalent even in children and adults, and hence, it is imperative to educate the public on the nutrition for bone health. “Love your bones and joints” was the slogan by the World Health Organization to increase the awareness among the public. Bone density is assessed by Dual Energy X-ray Absorptiometry scan and the T score system. Although biomarkers have been studied in research, their clinical utility is still elusive. Regular exercise and adequate intake of Calcium and Vitamin D are important to maintain bone health. Bisphosphonates are the first line drugs in the management of osteoporosis both for primary and secondary prophylaxis. Second-line drugs include denosumab, teriparatide, and newer drugs such as abaloparatide, romosozumab, and calcitonin, which have found more real-life acceptance and efficacious in the long-term management of osteoporosis. Romosozumab, a monoclonal antibody may well become the ideal osteoporosis drug with effects on bone formation and resorption. Surgical treatment choices include – Vertebroplasty and kyphoplasty are being accepted in specific instances and selected centers with variable success.
      Citation: Indian Journal of Rheumatology 2019 14(1):57-60
      PubDate: Thu,14 Mar 2019
      DOI: 10.4103/injr.injr_74_18
      Issue No: Vol. 14, No. 1 (2019)
       
  • Alopecia as the first manifestation of azathioprine myelosuppression in a
           genetically predisposed patient

    • Authors: Debashish Mishra, Shefali Khanna Sharma, Aman Sharma, Sanjay Jain, Varun Dhir
      Pages: 61 - 64
      Abstract: Debashish Mishra, Shefali Khanna Sharma, Aman Sharma, Sanjay Jain, Varun Dhir
      Indian Journal of Rheumatology 2019 14(1):61-64
      Azathioprine, an analog of mercaptopurine, is used for various inflammatory/autoimmune diseases in diverse fields such as rheumatology, ophthalmology, gastroenterology, and neurology. One of the dreaded side effects of this drug is myelosuppression, which can be either dose related or “idiosyncratic.” The latter group often manifests with sudden cytopenias and is often secondary to a genetic predisposition. Mutations in the genes thiopurine S-methyltransferase (TPMT) and nucleoside diphosphate-linked moiety X-type motif 15 (NUDT15) have been identified to predispose to severe myelosuppression with azathioprine. An important clinical clue that can precede the onset of myelosuppression is alopecia. Here, we describe the case of a young lady treated with azathioprine, who developed alopecia (progressing to alopecia totalis), which was followed by severe cytopenia – both of which recovered on stopping the drug. On genetic analysis, she was found to be homozygous for mutation in NUDT15 (C415T) but was negative for mutation in TPMT. We review various other cases reporting alopecia as a marker of azathioprine-induced myelosuppression and the genetic mutations described.
      Citation: Indian Journal of Rheumatology 2019 14(1):61-64
      PubDate: Thu,14 Mar 2019
      DOI: 10.4103/injr.injr_127_18
      Issue No: Vol. 14, No. 1 (2019)
       
  • Childhood polyarteritis nodosa presenting as central nervous system
           vasculitis

    • Authors: Sham Santhanam, Ravikumar Thambithurai, Nataraj Palaniappan, Mukul Vij, Srinivasan Kalyanasundaram
      Pages: 65 - 68
      Abstract: Sham Santhanam, Ravikumar Thambithurai, Nataraj Palaniappan, Mukul Vij, Srinivasan Kalyanasundaram
      Indian Journal of Rheumatology 2019 14(1):65-68
      Childhood polyarteritis nodosa (c-PAN) is one of the rare causes of childhood central nervous system (CNS) vasculitis. Nervous system involvement is less common, with peripheral nervous system frequently involved than the CNS. To the best of our knowledge, a very few cases of c-PAN presenting as CNS vasculitis involving both the anterior and posterior circulation have been reported in the literature. Hence, we report a 14-year-old female presenting with extensive CNS vasculitis with severe neurological deficits. She also had systemic symptoms, myalgia, leg ulcers, weight loss, axonal neuropathy, and proteinuria. She was treated with pulse methylprednisolone, monthly intravenous pulse cyclophosphamide, and intravenous immunoglobulin. At the end of 3 months, her proteinuria came down significantly with no major improvement in her neurological status. Hence, c-PAN has to be considered in the differential diagnosis of childhood CNS vasculitis and if not picked up early can lead to severe neurological deficits.
      Citation: Indian Journal of Rheumatology 2019 14(1):65-68
      PubDate: Thu,14 Mar 2019
      DOI: 10.4103/injr.injr_129_18
      Issue No: Vol. 14, No. 1 (2019)
       
  • Livedoid vasculopathy with mononeuritis multiplex associated with protein
           S deficiency mimicking systemic vasculitis

    • Authors: Vikramraj K Jain, Krishnamurthy Hegde, Renuka Panchagnula
      Pages: 69 - 73
      Abstract: Vikramraj K Jain, Krishnamurthy Hegde, Renuka Panchagnula
      Indian Journal of Rheumatology 2019 14(1):69-73
      A 34-year-old female presented with recurrent ulcers over the bilateral lower limbs with mononeuritis multiplex. Possibilities considered were small-to-medium vessel vasculitis and vasculopathy. Skin biopsy was suggestive of livedoid vasculopathy (LV). Investigations revealed protein S deficiency. The patient was treated with anticoagulation and immunosuppression after which her symptoms improved. LV can be associated with thrombophilias, fibrinolytic disorders, autoimmune diseases, and malignancy. Polyarteritis nodosa closely mimics the disease and needs a deep dermal biopsy to differentiate.
      Citation: Indian Journal of Rheumatology 2019 14(1):69-73
      PubDate: Thu,14 Mar 2019
      DOI: 10.4103/injr.injr_97_18
      Issue No: Vol. 14, No. 1 (2019)
       
  • Guillain–barre syndrome as a presenting feature of systemic lupus
           erythematosus in a child and it's complete resolution with rituximab
           treatment

    • Authors: Rahul Reddy, Anu Punnen, Annie Bella, Sathish Kumar
      Pages: 74 - 76
      Abstract: Rahul Reddy, Anu Punnen, Annie Bella, Sathish Kumar
      Indian Journal of Rheumatology 2019 14(1):74-76
      Systemic lupus erythematosus (SLE) can present with varied neurological manifestations in children. Guillain–Barre syndrome (GBS) as a presenting feature of SLE is quite rare in children. We report a 9-year-old girl who presented with acute motor axonal polyradiculoneuropathy and noticed to have features of SLE. She was initially treated with intravenous immunoglobulins and corticosteroids with partial response. After starting rituximab, she showed dramatic recovery, proving the role of rituximab in GBS refractory to first-line medications in SLE. She remained in remission after 12 months of follow-up.
      Citation: Indian Journal of Rheumatology 2019 14(1):74-76
      PubDate: Thu,14 Mar 2019
      DOI: 10.4103/injr.injr_118_18
      Issue No: Vol. 14, No. 1 (2019)
       
  • No impact of seronegativity on the efficacy of a biosimilar rituximab in
           biologic-naïve patients with active rheumatoid arthritis

    • Authors: Nedumooli Pottammal Jamshid, Vinod Ravindran
      Pages: 77 - 78
      Abstract: Nedumooli Pottammal Jamshid, Vinod Ravindran
      Indian Journal of Rheumatology 2019 14(1):77-78

      Citation: Indian Journal of Rheumatology 2019 14(1):77-78
      PubDate: Thu,14 Mar 2019
      DOI: 10.4103/injr.injr_158_18
      Issue No: Vol. 14, No. 1 (2019)
       
  • Use of coffee for alleviating methotrexate intolerance in rheumatic
           diseases

    • Authors: Anand Narayan Malaviya, Sadhana Singh Baghel, Shallu Verma, Ravita Thakran, Christy Messi
      Pages: 79 - 80
      Abstract: Anand Narayan Malaviya, Sadhana Singh Baghel, Shallu Verma, Ravita Thakran, Christy Messi
      Indian Journal of Rheumatology 2019 14(1):79-80

      Citation: Indian Journal of Rheumatology 2019 14(1):79-80
      PubDate: Thu,14 Mar 2019
      DOI: 10.4103/injr.injr_144_18
      Issue No: Vol. 14, No. 1 (2019)
       
  • A case of relapsing polychondritis with laryngeal stenosis successfully
           controlled with biosimilar adalimumab (ZRC-3197)

    • Authors: Manish Dugar, Jaswinder Singh Saluja, A Sudhakar
      Pages: 81 - 82
      Abstract: Manish Dugar, Jaswinder Singh Saluja, A Sudhakar
      Indian Journal of Rheumatology 2019 14(1):81-82

      Citation: Indian Journal of Rheumatology 2019 14(1):81-82
      PubDate: Thu,14 Mar 2019
      DOI: 10.4103/injr.injr_111_18
      Issue No: Vol. 14, No. 1 (2019)
       
  • Progressive pseudorheumatoid dysplasia: A mimicker of juvenile idiopathic
           arthritis

    • Authors: Sikha Agarwal, Anuja Pethe, Anuja Nayak
      Pages: 83 - 84
      Abstract: Sikha Agarwal, Anuja Pethe, Anuja Nayak
      Indian Journal of Rheumatology 2019 14(1):83-84

      Citation: Indian Journal of Rheumatology 2019 14(1):83-84
      PubDate: Thu,14 Mar 2019
      DOI: 10.4103/injr.injr_132_18
      Issue No: Vol. 14, No. 1 (2019)
       
  • Obituary Prakash Pispati

    • Authors: Rohini Handa
      Pages: 85 - 86
      Abstract: Rohini Handa
      Indian Journal of Rheumatology 2019 14(1):85-86

      Citation: Indian Journal of Rheumatology 2019 14(1):85-86
      PubDate: Thu,14 Mar 2019
      DOI: 10.4103/injr.injr_169_18
      Issue No: Vol. 14, No. 1 (2019)
       
 
 
JournalTOCs
School of Mathematical and Computer Sciences
Heriot-Watt University
Edinburgh, EH14 4AS, UK
Email: journaltocs@hw.ac.uk
Tel: +00 44 (0)131 4513762
Fax: +00 44 (0)131 4513327
 
About JournalTOCs
API
Help
News (blog, publications)
JournalTOCs on Twitter   JournalTOCs on Facebook

JournalTOCs © 2009-